LOCO-REGIONAL IMMUNOTHERAPY WITH RECOMBINANT INTERLEUKIN-2 AND ADHERENT LYMPHOKINE-ACTIVATED KILLER-CELLS (A-LAK) IN RECURRENT GLIOBLASTOMA PATIENTS

被引：28

作者：

BOIARDI, A ^{[1
]}

SILVANI, A ^{[1
]}

RUFFINI, PA ^{[1
]}

RIVOLTINI, L ^{[1
]}

PARMIANI, G ^{[1
]}

BROGGI, G ^{[1
]}

SALMAGGI, A ^{[1
]}

机构：

[1] IST NAZL TUMORI, I-20133 MILAN, ITALY

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 1994年 / 39卷 / 03期

关键词：

GLIOBLASTOMA; A-LAK; LOCO-REGIONAL IMMUNOTHERAPY;

D O I：

10.1007/BF01533386

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nine patients with recurrent glioblastoma were given autologous adherent lymphokine-activated killer (A-LAK) cells and interleukin-2 (IL-2) administered directly into the tumor cavity through an Ommaya tube placed during surgery/biopsy. The immunotherapy was well tolerated and the response rate was 33% (one complete response, two partial responses, four with stable disease and two with progressive disease). However, survival 18 months from initial diagnosis did not differ from that reported in the literature for patients treated conventionally. Serial determinations of IL-2 in the tumor cavity during the course of treatment revealed that IL-2 concentrations were sufficient to maintain lymphocyte activation. Since steroid medication was discontinued during treatment and A-LAK cells have greater antitumor activity than standard LAK cells, other factors are discussed that might explain the limited results.

引用

页码：193 / 197

页数：5

共 28 条

[1]

BURGER PC, 1991, RAD INJURY NERVOUS S, P236

[2] DEVELOPMENT OF MULTIPLE LESIONS DURING RADIATION-THERAPY AND CHEMOTHERAPY IN PATIENTS WITH GLIOMAS [J].